<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826279</url>
  </required_header>
  <id_info>
    <org_study_id>M-20110172B</org_study_id>
    <nct_id>NCT01826279</nct_id>
  </id_info>
  <brief_title>Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery</brief_title>
  <official_title>Short-term Investigation of Resveratrol on Lipid Turnover in Morbidly Obese Women Undergoing Gastric Bypass Surgery. Effects on Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism and Liver VLDL-triglyceride Uptake.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ministry of Science, Technology and Innovation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate potential metabolic effects of resveratrol in
      morbidly obese women undergoing gastric bypass surgery.

      The investigators hypothesize that resveratrol will:

        -  Decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion

        -  Decrease hepatic and adipose tissue VLDL-TG uptake

        -  Increase insulin sensitivity

      The investigators will look at changes in:

        -  Lipid turnover (VLDL-TG kinetics, palmitate kinetics,calorimetry)

        -  VLDL-TG uptake in different tissues (subcutaneous femoral adipose tissue, subcutaneous
           abdominal adipose tissue, visceral adipose tissue and liver tissue)

        -  Insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)

        -  Regulation of liver fat handling

        -  Lipoprotein lipase activity and fat cell size (abdominal and femoral adipose tissue)
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance</measure>
    <time_frame>1 month</time_frame>
    <description>- changes from baseline after treatment with either resveratrol or placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic and adipose VLDL-TG uptake</measure>
    <time_frame>1 month</time_frame>
    <description>- changes in VLDL-TG uptake in resveratrol group and placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Basal and insulin stimulated free fatty acid (FFA) and glucose turnover</measure>
    <time_frame>1 month</time_frame>
    <description>- changes from baseline after treatment with either resveratrol or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-TG oxidation</measure>
    <time_frame>1 month</time_frame>
    <description>- changes from baseline after treatment with either resveratrol or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regulation of liver fat handling</measure>
    <time_frame>1 month</time_frame>
    <description>- changes in regulation of liver fat handling in resveratrol group and placebo group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol 500mg 3 times daily for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tablet 3 times daily for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>500mg 3 times daily for 1 month</description>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 placebo tablet 3 times daily for 1 month</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  25-60 years

          -  Obesity (BMI &gt; 35 kg/m2)

          -  Have at least one element of the metabolic syndrome either hypertension and/or
             hypercholesterolemia (high triglyceride, low HDL-cholesterol)

          -  Undergoing gastric bypass surgery

          -  Written informed consent

        Exclusion Criteria:

          -  Any other relevant disease (e.g. diabetes, thyroid or parathyroid disease, heart,
             kidney or liver disease)

          -  May have arthrosis or depression

          -  Any present or previous malignancy

          -  History of smoking

          -  Alcohol dependency (more than 14 units of alcohol per week)

          -  Participation in studies with radioactive isotope within the last six months

          -  Hemoglobin under the normal range regarding to sex (under 7.3 mmol/l for women)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SÃ¸ren Nielsen, MD, associate professor, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Endocrinology and Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Medicine</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2013</study_first_submitted>
  <study_first_submitted_qc>April 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Gastric bypass surgery</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Lipid turnover</keyword>
  <keyword>VLDL-triglyceride uptake</keyword>
  <keyword>Liver</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

